readers say

The legalization of psychedelic substances in Massachusetts has drawn national attention and divided some Mass. voters on either side of the vote as Nov. 5 approaches.

The ballot measure's major proponent, Massachusetts for Mental Health Options (MMHO)says Question 4, outlining a comprehensive plan to treat adults over the age of 21 with serious mental illnesses “under the supervision and guidance of a trained, licensed professional in regulated treatment centers,” in response to its website.

“Psychedelics are known to produce a profound change in consciousness, often experienced as something deeply meaningful, important or profound event,” said Dr. Franklin King, lecturer at Harvard Medical School and director of education and training on the Mass. Generally Center for Neuroscience of Psychedelics.

If voters vote “yes” on Question 4, Mass third state within the nation There are laws allowing adult use of psychedelic drugs, lagging behind Colorado and Oregon.

“[Psychedelics] create very powerful, powerful states. These should not be taken lightly,” said Dr. King. “Certainly it can be a very challenging experience for some people. There are a lot of things that can potentially go wrong, just as a really positive experience with psychedelics can leave lasting change.”

Founding partner of Shawmut Strategies and spokesperson for Coalition for Safe CommunitiesChris Keohan, is amongst Massachusetts voters confident of voting “no” this fall.

“We do not question the medical benefits of this under medical supervision. But this goes a significant step too far and reduces the overall safety of people here in Massachusetts,” Keohan said. “Not only with the additional problems of driving under the influence of alcohol or drugs, but also with the problems that would come with the growth of the home for children, pets, etc. [and] Household contents insurance in general.”

The coalition's major concern with the ballot measure is the power to grow psychedelics at home. The measure would make this possible as much as 144 square meters have grown. The Minimum dimensions A main bedroom within the state is 120 square feet.

“That’s an astronomical amount of square footage for home improvement,” Keohan said. “If homeownership growth wasn't taken into account, I probably wouldn't be involved on the 'no' side of this ballot question. The fact that this is the case, I think, poses a really significant threat to public safety.”

While some voters support general legalization, they worry about access restrictions.

This applies to the leadership of Bay Staters for Natural Medicinea community group dedicated to educating its members concerning the use of psychedelic drugs.

“Eight cities and counting have already indicated they want this policy implemented,” said James Davis, executive director and co-founder of Bay Staters for Natural Medicine. “If we just implement this, in some ways it's the best form of legalization because it means people are getting this drug from someone they know and growing it themselves.”

Still, there are differing opinions about how psychedelic drugs needs to be regulated within the state.

“We never thought a ballot question would be viable in the state of Massachusetts,” Davis said. “We don't believe we exist from the perspective of public opinion, and that's why we exist.” Educating slowly, having tough conversations, meeting with individuals who don't agree with us, and not only attempting to force it through , by getting 51% of the vote.”

“That’s really what we want as an alternative form of legalization,” he said.

Following the announcement of the certified ballot questions, Boston.com polled readers whether or not they consider psychedelic mental health care needs to be legalized within the state. Of the full 430 responses, 74% voted “yes,” 21 voted “no,” and 4% voted “I don’t know.”

Based on reader responses, two of probably the most common themes and concerns surrounding legalization were public safety and mental health.

Here's a collection of what readers said and the way they plan to vote on Question 4.

Yes: Psychedelics promote mental health

Of nearly all of “yes” votes, readers commented on what psychedelic-assisted therapy could do in managing PTSD and other serious mental health diagnoses. Dr. King said, “The patient has to do a lot of work, just being open to the experience and not shying away from negative things that might come up.”

“People hear psychedelic and forget the word therapy,” added Dr. King added. “I think this is simply an exploration of the contemporary issues that we can probably expect more of when it comes to psychedelics.”

“Post-traumatic stress disorder is a debilitating, agonizing illness that claims countless lives through suicide and devastates many more. Veterans, first responders and BIPOC people are disproportionately affected. Conventional medications and psychotherapy are not enough to help these people. But research at Johns Hopkins, Columbia and other universities has shown remarkable and rapid benefits from short courses of psilocybin. The bias of the Nixon era cost us 50 years of unnecessary suffering. It’s time.”

–

“For medical and psychological purposes only – not for recreational purposes. The data is compelling.”

–

“This medication is so important for those struggling with PTSD or childhood trauma. It allows us to overcome our fears and find self-care and love within ourselves. Dr. Bessel van der Kolk, the leading psychiatrist in trauma therapy, has studied this and is a proponent of this type of treatment. It is discussed in his best-selling book, The Body Keeps the Score.”

–

“If this natural mushroom can help someone heal, it should be available to them. The more natural medicines there are, the better they are for the body and our planet.”

–

“Psychedelic mushrooms have been used for thousands of years and there is clearly a reason for this. It makes no sense that these mushrooms are still illegal when other substances, such as alcohol, which are generally more harmful, are not.”

–

No: I’m concerned about public safety

A typical reason readers vote “no” is concern concerning the potential detrimental impact this access could have. Keohan advises people to “listen to medical professionals.” Listen to the psychiatrists.”

“For the mental health of the clinic, yes. For recreational purposes, no. We have seen an increase in drug abuse since the legalization of marijuana. Our energy should go toward treatment rather than legalization.”

“Psychedelics have been proven not to be medicine in their own right. What psychedelic research has shown is the potential therapeutic effectiveness of psychedelic-assisted therapy in highly structured/supportive environments. These substances actually pose mental/mental health risks that need to be better understood before their access is expanded in the real world. The premature legalization process may have unintended negative impacts on public mental health, with certain vulnerable populations (e.g., high-risk youth) being most at risk.”

–

Risks are known. The advantages are limited. Can be “administered” at home, path to abuse.”

–

“I’m an emergency room nurse. Since marijuana was legalized, the number of traumatic cases I see due to cannabis use has skyrocketed. In some patients I can smell it; others admit to consuming edibles. Most recently, I took the vitals of a driver who passed out during shatter therapy and broke both femurs of the driver whose car he hit with his pickup truck. Human nature is what it is and “patients” will abuse this “medicine” and cause everlasting harm to others. In the case of alcohol, the police could conduct a blood or breath test on site to detect excessive alcohol consumption. Not so with previously illegal drugs.”

–

“One wonders whether the item would not be taxed if we pursued this. Things that distort normal cognitive function don’t seem to benefit.”

–

I'm undecided

“I think we should legalize them. I do not think that the part of the bill that requires it to be adopted within the framework of licensed, very expensive “health” centers (for large profits for private companies) should be included or allowed in this bill. These useful drugs should be decriminalized and allowed to be used by health centers without reservation. We don't do that with marijuana. This should not happen in this case either. It restricts access to very wealthy people, and people with mental health problems who are not wealthy will be denied access under this proposed law.”

–

“I don't know enough about them to give a fair opinion, but when something is described as 'psychedelic,' isn't that tantamount to distorting reality? I’m not sure how altering reality could be of any use to anyone.”

–

Drugmaker Lykos Therapeutics announced on August 9, 2024 that the Food and Drug Administration refused to grant the corporate’s request for using MDMA-assisted therapy within the treatment of Posttraumatic stress disorderThis is the primary decision of its kind on an application for marketing authorization for a psychedelic drug.

Many investors and researchers were Predicting a Psychedelic BoomMDMA is just the primary of a variety of psychedelics within the drug development pipeline.

The FDA’s decision has Disappointed supporters of psychedelic therapyand the share prices of Psychedelics Industry Leaders with the announcement. However, the FDA made recommendations on how the applying might be improved in order that MDMA could receive approval in the long run.

Another setback followed a couple of days later when the journal Psychopharmacology three papers on MDMA-assisted therapy withdrawnand referred to “protocol violations that amount to unethical behavior,” particularly in a clinical trial.

The Conversation asked drug researchers Benjamin Y. Fong from Arizona State University on the implications of the FDA decision and what it means for the long run of psychedelic medicines.

What is MDMA and what forms of illnesses can it treat?

MDMA or midomafetamineis colloquially referred to as “molly” or “ecstasy.” Technically it’s an amphetamine – just like the energetic ingredient in the eye deficit hyperactivity disorder drug Adderall – but MDMA is commonly classified as a psychedelic. It is taken into account to be more pleasurable than other amphetamines and is a preferred party drug because of this. Some researchers check with MDMA as an “empathogen” or “feeling enhancer.”

While MDMA is currently a List I medicinal products – meaning the Drug Enforcement Administration considers it highly dangerous and has no recognized medical use – a series of clinical studies indicate the advantages of using MDMA together with talk therapy for Patients affected by PTSDThe FDA received breakthrough therapy status for MDMA-assisted therapy in 2017, which accelerated its development and review.

PTSD affects between 9 to 13 million people annually within the USA and no novel treatments developed for this disease.

Lykos Therapeutics submitted an application for FDA approval its version of MDMA-assisted therapy for PTSD in February 2024. In it, the drug is paired with a form of psychotherapy that “inner healing intelligence“, which Lykos defined as “a person’s innate ability to heal the wounds of trauma.”

Why did the FDA reject approval of Lykos’ MDMA-assisted therapy?

In June 2024, a FDA advisory committee voted overwhelmingly against the concept that the relevant clinical trials have proven the effectiveness of MDMA in treating PTSD. Equally crucial is the The committee also voted against the thought It has been shown that the advantages outweigh the risks, comparable to increased blood pressure and potential for abuse.

At the time, the advisory committee found fault with several points of Lykos' application. First, it pointed to the issue of “functional unblinding,” the undeniable fact that most trial participants would know whether or not they were taking a robust psychoactive substance, which might skew the outcomes. This is an issue with any psychoactive drug, and Lykos critics imagine the corporate must have followed FDA policy to make use of an “active placebo” – a placebo that also has psychoactive effects – for comparison in its earlier clinical trials.

The panel also asked questions on the shape of psychotherapy used alongside MDMA, in addition to ethical concerns about various types of misconduct in Lykos' studies. In certainly one of the corporate's studies, a participant reported sexual misconduct by the therapists involved.

The FDA is just not sure by the votes of such advisory bodies, however it follows her leadTherefore, Friday’s decision was not an enormous surprise.

What does the FDA’s decision mean for the long run of MDMA?

The FDA requested a additional Phase 3 studythe phase of clinical trials wherein the security and effectiveness of a specific treatment is rigorously demonstrated as compared to straightforward treatment.

Lykos said the corporate will request a review of the choice and discuss the FDA's recommendations with the agency to make sure the corporate is on the proper track.

Lykos CEO Amy Emerson, who described the choice as “deeply disappointing,” believes that “several years” to perform the brand new process.

But with the journal Psychopharmacology Withdrawal of three articles related to this workLykos has a difficult road ahead of him.

What impact could this decision have on the approval of other psychedelic drugs?

A outstanding psychedelics company, Compass Pathways, is widely considered next in line for FDA approval of a psychedelic drug, with Phase 3 clinical trials for its synthetic psilocybin are well underway. Other corporations are preparing Phase 3 trials of their very own proprietary compounds.

Following the advisory panel’s ruling in June, Compass stated that it not mate his drug with a therapy just like the one Lykos carried out. Another company claimed that it has a “better study design that is more consistent with FDA guidelines.”

Other psychedelic corporations clearly imagine they’ll succeed where Lykos failed.

Are there any special challenges related to psychedelics?

The FDA’s decision was more about Lykos' specific approach than an entire rejection of psychedelics for therapeutic use.

Yet developing psychedelic drugs is inherently a fragile process. The drugs induce a profoundly altered state that puts people in a vulnerable position. Some people within the industry I've spoken to imagine that, given the character of the experience, it's almost inconceivable to avoid accusations of impropriety.

Most research also combines psychedelic drugs with some type of therapy or relief, and because the FDA has made clear, their role Evaluate medicinesnot the psychotherapies that may accompany it.

The interaction between the drugs and the human think about treatment is the topic of some debate. Lykos' missteps in its application make clear among the ways wherein corporations involved in developing psychedelic drugs face unique obstacles on the road to FDA approval.